Ignite Creation Date:
2024-05-06 @ 8:13 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06309277
Status:
RECRUITING
Last Update Posted:
2024-04-04
First Post:
2024-01-29
Brief Title:
A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD
Sponsor:
Gilgamesh Pharmaceuticals
Organization:
Gilgamesh Pharmaceuticals
Study Overview
Official Title:
A Two-Part Controlled Clinical Study to Evaluate Safety Tolerability Response Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of GM-1020 in Patients With Major Depressive Disorder
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and preliminary antidepressant efficacy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None